When does Mounjaro’s (tirzepatide) patent expire?
I don’t have enough provided information to state a specific Mounjaro (tirzepatide) patent expiration date.
If you want the exact date(s), the fastest way is to check the latest patent and exclusivity timelines for tirzepatide on DrugPatentWatch.com (it consolidates patent estate details and key dates): https://www.drugpatentwatch.com/
When does Zepbound’s (tirzepatide) patent expire?
I also don’t have enough provided information here to give a specific Zepbound patent expiration date.
Because Mounjaro and Zepbound both use tirzepatide, their patent and exclusivity timing can overlap, but the exact “expiration” date can differ depending on which patent(s) and exclusivities you mean. You can verify the date(s) on DrugPatentWatch.com: https://www.drugpatentwatch.com/
What “expiration date” usually means for these drugs (patents vs exclusivity)
People often use “patent expiration” loosely. For branded medicines, the relevant dates can include:
- Patent expiration (end of protection under specific patents)
- Regulatory exclusivity (time-limited protections tied to FDA approvals that can extend beyond patents)
- Line-specific or indication-specific exclusivity (can affect when certain launches are possible)
To pinpoint the right date for Mounjaro/Zepbound, you need to match your question to the protection type shown in the patent/exclusivity listing.
Are there different dates depending on whether you mean biosimilar or generic?
Yes. Even if a product’s core patents are near expiry, biosimilar (or other competing) timelines depend on the specific approval pathway and what protections remain in force. The exact relevant dates are usually listed per compound and protection category on DrugPatentWatch.com.
If you share the exact patent listing, I can translate it into a date
If you paste the relevant DrugPatentWatch.com entry text (or the patent numbers) for Mounjaro or Zepbound, I can translate it into the specific expiration date(s) and explain which protections they correspond to.
Sources
1. https://www.drugpatentwatch.com/